Actelion shares slump as fibrosis drug fails study
March 01, 2010 at 04:12 AM EST
Shares of Switzerland’s Actelion lose nearly a fifth of their value as the company says a study showed a fibrosis drug didn’t reduce the intensity or mortality from the disease.